tools and integrated systems for the large-scale analysis of genetic
variation and biological function.
Developer of innovative small molecule cancer treatments based on a
molecular understanding of cancer. Onyx's lead product is Nexavar(R)
(sorafenib) tablets, an oral multiple kinase inhibitor that targets
proteins involved in both tumor cell proliferation and angiogenesis
(the formation of new blood vessels to support cancer cell growth).
The Company is leading the development of the HCV protease inhibitor,
telaprevir (VX-950), and in 2007 is conducting a broad Phase 2
clinical program of this drug candidate. Vertex is also focused on the
development of VX-702, a p38 MAP kinase inhibitor for the treatment of
rheumatoid arthritis, and VX-770, an investigational drug candidate
for cystic fibrosis.
Special Recognition for an Individual
Jim Greenwood, President and CEO, Biotechnology Industry Organization
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations in
all 50 U.S. states and 31 other nations.
Susan D. Desmond-Hellmann, President, Product Development, Genentech
Genentech is one of the biotech industry's leading companies and Dr.
Desmond-Hellmann has overseen the development of several promising
cancer drugs and the final testing phase of others.
John C. Martin, President and CEO, Gilead Sciences Inc.
Dr. Martin joined Gilead Sciences in 1990 and has served as President
and Chief Executive Officer since 1996. The company has expanded
rapidly over the past two decades, with annual revenues now exceeding
|SOURCE Burrill & Company|
Copyright©2007 PR Newswire.
All rights reserved